Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents.
Neurologic abnormalities are among the most serious extraintestinal complications of infection with Shiga toxin (Stx)-producing bacteria. Histopathologic examination of tissues from patients with extraintestinal sequelae suggested that Stxs damage endothelial cells. It is shown here that human brain microvascular endothelial cells (HBMECs) are relatively resistant to purified Stxs (50% cytotoxic doses [CD50s] >/=10 microgram/mL). Pretreatment of HBMECs with tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, n-butyric acid, or a cAMP analogue resulted in a 103- to 104-fold decrease in CD50 values and a 2- to 4-fold increase in fluoresceinated Stx binding to HBMECs. Treatment of HBMECs with lipopolysaccharides did not significantly alter cytotoxicity or toxin binding. TNF-alpha and IL-1beta treatment was associated with the increased HBMEC expression of the toxin-binding glycolipid globotriaosylceramide. HBMECs did not produce IL-1beta and produced only trace amounts of TNF-alpha when stimulated with purified Stx1 in vitro.
Ramegowda
B
B
Department of Medical Microbiology, Texas A&M University Health Science Center, College Station, Texas 77843-1114, USA. belakere@hotmail.com
Samuel
J E
JE
Tesh
V L
VL
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000293:Adolescent; D001427:Bacterial Toxins / Q000633:toxicity*; D002470:Cell Survival / Q000187:drug effects; D002540:Cerebral Cortex / Q000098:blood supply*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003603:Cytotoxins / Q000633:toxicity*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology*; D006017:Glycolipids / Q000302:isolation & purification; D006801:Humans; D007249:Inflammation; D007375:Interleukin-1 / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D008833:Microcirculation / Q000187:drug effects / Q000473:pathology*; D011994:Recombinant Proteins / Q000633:toxicity; D022603:Shiga Toxins; D012760:Shigella; D014281:Trihexosylceramides / Q000302:isolation & purification / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D001427:Bacterial Toxins; D003603:Cytotoxins; D006017:Glycolipids; D007375:Interleukin-1; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D022603:Shiga Toxins; D014281:Trihexosylceramides; D014409:Tumor Necrosis Factor-alpha; D015124:8-Bromo Cyclic Adenosine Monophosphate; C018549:globotriaosylceramide